Determine effectiveness of Anifrolumab In SYstemic sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 70 Years
- Sexes
- All
M23 Select SLE
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 63 Years
- Sexes
- All
KZR-616-202
The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All